RSPI (RespireRx Pharmaceuticals) Effective Interest Rate on Debt %: 10.33% (As of Sep. 2023)

What is RespireRx Pharmaceuticals Effective Interest Rate on Debt %?

RespireRx Pharmaceuticals RSPI 12 Effective Interest Rate on Debt % is 10.33% as of Sep. 2023. GuruFocus rates RSPI with a GF Score™ of 12/100.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. RespireRx Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Sep. 2023 was $0.29 Mil. RespireRx Pharmaceuticals's average total debt for the quarter that ended in Sep. 2023 was $2.83 Mil. Therefore, RespireRx Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2023 was 10.33%.

RespireRx Pharmaceuticals (OTCPK:RSPI) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

RespireRx Pharmaceuticals Effective Interest Rate on Debt % Related Terms

RespireRx Pharmaceuticals Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals Effective Interest Rate on Debt % Chart

RespireRx Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

11.34

28.09

32.91

38.54

25.24

RespireRx Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															15.28	10.64	9.64	31.43	10.33

RSPI vs CNBX, NAVB, IPIX: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RespireRx Pharmaceuticals Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Effective Interest Rate on Debt % falls into.

Save Embed

12GF Score

RespireRx Pharmaceuticals Inc RSPI

Effective Interest Rate on Debt % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

RespireRx Pharmaceuticals Effective Interest Rate on Debt % Calculation

RespireRx Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2021 )	+	Total Debt (A: Dec. 2022 ))	/ count )
=	-1 * -0.604	/	( (2.078	+	2.709)	/ 2 )
=	-1 * -0.604	/	2.3935
=	25.24 %

where

	Total Debt (A: Dec. 2021 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.078
=	2.078

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.709
=	2.709

RespireRx Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Jun. 2023 )	+	Total Debt (Q: Sep. 2023 ))	/ count )
=	-1 * -0.292	/	( (2.873	+	2.781)	/ 2 )
=	-1 * -0.292	/	2.827
=	10.33 %

where

	Total Debt (Q: Jun. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.873
=	2.873

	Total Debt (Q: Sep. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.781
=	2.781

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Sep. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about Effective Interest Rate on Debt % →

What does a Effective Interest Rate on Debt % of 10.33% mean?

RespireRx Pharmaceuticals (RSPI) has a Effective Interest Rate on Debt % of 10.33% as of Sep. 2023. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on RespireRx Pharmaceuticals and its competitors.

Is RespireRx Pharmaceuticals' Effective Interest Rate on Debt % too high?

RespireRx Pharmaceuticals' current Effective Interest Rate on Debt % is 10.33%. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does RespireRx Pharmaceuticals' Effective Interest Rate on Debt % compare to CNBX and NAVB?

RespireRx Pharmaceuticals' Effective Interest Rate on Debt % of 10.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Effective Interest Rate on Debt % for a Biotechnology company?

A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Effective Interest Rate on Debt % mean?

A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current Effective Interest Rate on Debt % is 10.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is RespireRx Pharmaceuticals stock overvalued right now?

RespireRx Pharmaceuticals (RSPI) has a current Effective Interest Rate on Debt % of 10.33%. The current Effective Interest Rate on Debt % is 10.33%. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Effective Interest Rate on Debt % calculated?

Effective Interest Rate on Debt % is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current Effective Interest Rate on Debt % is 10.33% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CNBX NAVB IPIX PPCB ATRX PKBO EFTR ARDS NYMXF IVRN OCSE:NOVO B REGN VRTX ASX:CSL XKRX:207940 ALNY XBRU:UCB XKRX:068270 MRNA XBRU:ARGX

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452

Website http://www.respirerx.com

RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.

12GF Score

Get the complete analysis for RSPI

Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View RSPI Analysis

See Effective Interest Rate on Debt % data for all stocks →